Targeted Drug with Chemotherapy Combo Offers Longer Life to Patients with B-cell Cancers

CHICAGO — Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), an interim analysis has closed the international HELIOS phase III clinical trial. Led by Mayo Clinic, researchers found that ibrutinib and chemotherapy (bendamustine and rituximab, known as [...]
Source: News from Mayo Clinic - Category: Databases & Libraries Source Type: news